Addendum: Resolvins suppress tumor growth and enhance cancer therapy.

Authors:
Sulciner ML; Serhan CN; Gilligan MM; Mudge DK; Chang J and 16 more

Journal:
J Exp Med

Publication Year: 2024

DOI:
10.1084/jem.2017068101232024a

PMCID:
PMC10829511

PMID:
38294489

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-d…
Ruggiu M; Guérin MV; Corre B and 9 more (2024) - Transparency Score: 3/6
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P; Gervais A; Taniguchi M and 87 more (2024) - Transparency Score: 3/6
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L; Xiao Y; Luo Y and 19 more (2024) - Transparency Score: 5/6
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M; Schmidleithner L; Simon M and 32 more (2024) - Transparency Score: 4/6
A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design.
Sengupta S; Zhang J; Reed MC and 15 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"vol 215 no 1 | https://doi org/10 1084/jem 20170681 | november 30 2017 after publication it came to jem 's attention that the article did not include any information for readers to access the raw data of fig s3 j and k these data have now been deposited in the biostudies database ( https://www ebi ac uk/biostudies/ ) and can be accessed with the accession number s-bsst1262."

Code Sharing
COI Disclosure
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025